Our Pipeline
We have a broad pipeline of novel drugs that have potential to become first-in-class or best-in-class medicines for a range of diseases.
We are developing molecules both in-house and with partners to ensure that our medicines have the best chances of reaching patients in need.
In-house Programs
Our emerging pipeline of in-house programs comprise multiple drug candidates that address patient populations across our key focus areas of neurology, GI and immunology, metabolic disorders and rare diseases.
Daridorexant
Indication
Insomnia
Modality
Small molecule
GPR52 agonist
Indication
Schizophrenia
Modality
Small molecule
Candidate
NXE0048149
EP4 antagonist
Indication
Immuno-oncology
Modality
Small molecule
Candidate
NXE0039732
Partner
Cancer Research UK
EP4 agonist
Indication
Inflammatory Bowel Disease
Modality
Small molecule
Candidate
NXE0033744
Muscarinic M1-preferring agonist (Japan)
Indication
Neurology
Modality
Small molecule
Candidate
NBI-1117567
GPR35 agonist
Indication
Inflammatory bowel disease/GI disorders
Modality
Small molecule
Candidate
NXE0027477